Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19

<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><ul type="disc"><li>Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment</li><li>Preclinical data suggest VIR-7832 has two distinguishing properties: enhanced ability to clear infected cells and…

This post was originally published on this site